LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES

被引：1
|
作者：
Tachdjian, R.
Anderson, J.
Busse, P.
Johnston, D.
Kiani, S.
Nurse, C.
Paes, K.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2018年 / 121卷 / 05期
关键词：
D O I：
10.1016/j.anai.2018.09.119
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P171
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [31] Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study
    Fabregues, O.
    Tolosa, E.
    Ferreira, J.
    Lees, A.
    Santos, A.
    Arbe, E.
    Rocha, J-F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2018, 33 : S142 - S142
  • [32] Efficacy of Bremelanotide for HSDD in Women: RECONNECT Open-Label Extension Phase Results
    Clayton, Anita H.
    Kingsberg, Sheryl A.
    Simon, James A.
    Jordan, Robert
    Lucas, Johna
    OBSTETRICS AND GYNECOLOGY, 2018, 131 : 186S - 186S
  • [33] The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
    Baldwin, David S.
    Chrones, Lambros
    Florea, Ioana
    Nielsen, Rebecca
    Nomikos, George G.
    Palo, William
    Reines, Elin
    JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (03) : 242 - 252
  • [34] Efficacy of Bremelanotide for HSDD in Women: Reconnect Open-Label Extension Phase Results
    Clayton, Anita
    Kingsberg, Sheryl
    Simon, James
    Jordan, Robert
    Lucas, Johna
    JOURNAL OF WOMENS HEALTH, 2018, 27 (04) : 4 - 4
  • [35] Consistent Reduction in HAE Attack Rate with Lanadelumab Regardless Of Baseline Attack Frequency: Interim Findings From the Phase 3 HELP Study Open Label Extension (OLE)
    Banerji, Aleena
    Riedl, Marc
    Tachdjian, Raffi
    Nurse, Christina
    Paes, Kim
    Li, Huamin
    Kiani-Alikhan, Sorena
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB103 - AB103
  • [36] SWITCHING FROM DOUBLE-BLIND ENTACAPONE OR PLACEBO TO OPEN-LABEL OPICAPONE: NMSS RESULTS (1-YEAR EXTENSION BIPARK-I STUDY)
    Fabregues, O.
    Tolosa, E.
    Ferreira, J.
    Lees, A.
    Santos, A.
    Rocha, J.
    Soares-Da-Silva, P.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (12) : E49 - E49
  • [37] LANADELUMAB FOR PREVENTION OF ATTACKS IN HEREDITARY ANGIOEDEMA: RESULTS FROM THE PHASE 3 HELP STUDY
    Banerji, A.
    Riedl, M.
    Bernstein, J.
    Cicardi, M.
    Longhurst, H.
    Zuraw, B.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S5 - S5
  • [38] Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial
    Nitzan, U.
    EUROPEAN PSYCHIATRY, 2023, 66 : S845 - S846
  • [39] Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial
    Nitzan, Uri
    Carmeli, Gal
    Chalamish, Yossi
    Braw, Yoram
    Kirsch, Irving
    Shefet, Daphna
    Krieger, Israel
    Mendlovic, Shlomo
    Bloch, Yuval
    Lichtenberg, Pesach
    JOURNAL OF AFFECTIVE DISORDERS, 2020, 276 : 707 - 710
  • [40] Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial
    Nitzan, U.
    EUROPEAN PSYCHIATRY, 2023, 66 : S845 - S846
12345